|
US4971791A
(en)
*
|
1985-08-26 |
1990-11-20 |
The Procter & Gamble Company |
Taste masking compositions
|
|
US5843445A
(en)
*
|
1987-06-24 |
1998-12-01 |
Autoimmune, Inc. |
Method of treating rheumatoid arthritis with type II collagen
|
|
US4857337A
(en)
*
|
1988-05-24 |
1989-08-15 |
American Home Products Corp. (Del) |
Enteric coated aspirin tablets
|
|
BR9106114A
(pt)
|
1990-03-02 |
1993-03-09 |
Autoimmune Inc |
Metodo para tratar ou prevenir uma doenca auto-imune (ad) e formulacao farmaceutica
|
|
FR2660317B1
(fr)
*
|
1990-03-27 |
1994-01-14 |
Seppic |
Produit filmogene destine a l'enrobage des formes solides; son procede de fabrication et produits revetus de ce produit.
|
|
IL99699A
(en)
*
|
1990-10-10 |
2002-04-21 |
Autoimmune Inc |
Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
|
|
US5427614A
(en)
*
|
1992-02-14 |
1995-06-27 |
Warner-Lambert Company |
Starch based formulations
|
|
US6224911B1
(en)
*
|
1993-03-16 |
2001-05-01 |
Syntex (U.S.A.) Llc |
Process for the preparation of enteric coated pharmaceutical dosage forms
|
|
US5436011A
(en)
*
|
1993-04-16 |
1995-07-25 |
Bristol-Myers Squibb Company |
Solid pharmaceutical dosage form and a method for reducing abrasion
|
|
US5800831A
(en)
*
|
1993-07-28 |
1998-09-01 |
Pfizer Inc. |
Psoriasis treatment with polymer film
|
|
US6113893A
(en)
*
|
1993-07-28 |
2000-09-05 |
Pfizer Inc. |
Psoriasis treatment
|
|
CA2164344C
(en)
*
|
1993-08-30 |
2004-06-29 |
Stanley Lech |
Tablet coating based on a melt-spun mixture of a saccharide and a polymer
|
|
DE69522921T2
(de)
*
|
1994-07-08 |
2002-04-11 |
Astrazeneca Ab |
Aus mehreren einzeleinheiten zusammengesetzte dosierungsform in tablettenform (i)
|
|
US5733575A
(en)
*
|
1994-10-07 |
1998-03-31 |
Bpsi Holdings, Inc. |
Enteric film coating compositions, method of coating therewith, and coated forms
|
|
US6645943B1
(en)
|
1994-10-25 |
2003-11-11 |
Hybridon, Inc. |
Method of down-regulating gene expression
|
|
US5591721A
(en)
*
|
1994-10-25 |
1997-01-07 |
Hybridon, Inc. |
Method of down-regulating gene expression
|
|
US6608035B1
(en)
|
1994-10-25 |
2003-08-19 |
Hybridon, Inc. |
Method of down-regulating gene expression
|
|
SE9500422D0
(sv)
*
|
1995-02-06 |
1995-02-06 |
Astra Ab |
New oral pharmaceutical dosage forms
|
|
US5683718A
(en)
*
|
1995-04-04 |
1997-11-04 |
Time-Cap Labs, Inc. |
Enteric coated tablet with raised identification character and method of manufacture
|
|
US5856446A
(en)
*
|
1995-07-07 |
1999-01-05 |
Autoimmune Inc. |
Method of treating rheumatoid arthritis with low dose type II collagen
|
|
US6624293B1
(en)
|
1995-08-17 |
2003-09-23 |
Hybridon, Inc. |
Modified protein kinase A-specific oligonucleotides and methods of their use
|
|
US7074768B2
(en)
|
1995-08-17 |
2006-07-11 |
Idera Pharmaceuticals, Inc. |
Modified protein kinase A-specific oligonucleotides and methods of their use
|
|
SE512835C2
(sv)
*
|
1996-01-08 |
2000-05-22 |
Astrazeneca Ab |
Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
|
|
SE9600071D0
(sv)
|
1996-01-08 |
1996-01-08 |
Astra Ab |
New oral formulation of two active ingredients I
|
|
SE9600072D0
(sv)
*
|
1996-01-08 |
1996-01-08 |
Astra Ab |
New oral formulation of two active ingredients II
|
|
SE9600070D0
(sv)
|
1996-01-08 |
1996-01-08 |
Astra Ab |
New oral pharmaceutical dosage forms
|
|
US5807580A
(en)
*
|
1996-10-30 |
1998-09-15 |
Mcneil-Ppc, Inc. |
Film coated tablet compositions having enhanced disintegration characteristics
|
|
US20070149472A1
(en)
*
|
1997-08-13 |
2007-06-28 |
Mckay Robert |
Antisense oligonucleotide compositions and methods for the modulation of jnk proteins
|
|
US6133246A
(en)
*
|
1997-08-13 |
2000-10-17 |
Isis Pharmaceuticals Inc. |
Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
|
|
US5877309A
(en)
|
1997-08-13 |
1999-03-02 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides against JNK
|
|
US6809193B2
(en)
|
1997-08-13 |
2004-10-26 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
|
|
JP2001514884A
(ja)
|
1997-08-19 |
2001-09-18 |
ハイブリドン・インク |
新規なｈｉｖ特異的合成オリゴヌクレオチド及びその使用方法
|
|
EP0901787B1
(en)
*
|
1997-09-10 |
2003-05-28 |
Takeda Chemical Industries, Ltd. |
Stabilized pharmaceutical composition
|
|
US6559158B1
(en)
|
1997-11-03 |
2003-05-06 |
Ur Labs, Inc. |
Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
|
|
US6274591B1
(en)
*
|
1997-11-03 |
2001-08-14 |
Joseph F. Foss |
Use of methylnaltrexone and related compounds
|
|
US20030158220A1
(en)
*
|
1997-11-03 |
2003-08-21 |
Foss Joseph F. |
Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
|
|
UA69413C2
(uk)
|
1998-05-22 |
2004-09-15 |
Брістол-Майерс Сквібб Компані |
Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
|
|
US7122207B2
(en)
*
|
1998-05-22 |
2006-10-17 |
Bristol-Myers Squibb Company |
High drug load acid labile pharmaceutical composition
|
|
UA73092C2
(uk)
|
1998-07-17 |
2005-06-15 |
Брістол-Майерс Сквібб Компані |
Таблетка з ентеросолюбільним покриттям і спосіб її приготування
|
|
US6300320B1
(en)
|
1999-01-05 |
2001-10-09 |
Isis Pharmaceuticals, Inc. |
Modulation of c-jun using inhibitors of protein kinase C
|
|
US6432448B1
(en)
|
1999-02-08 |
2002-08-13 |
Fmc Corporation |
Edible coating composition
|
|
US6723342B1
(en)
|
1999-02-08 |
2004-04-20 |
Fmc Corporation |
Edible coating composition
|
|
US6878749B2
(en)
|
1999-09-17 |
2005-04-12 |
Novartis Ag |
Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
|
|
US6559188B1
(en)
|
1999-09-17 |
2003-05-06 |
Novartis Ag |
Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
|
|
US6812205B2
(en)
|
2000-03-15 |
2004-11-02 |
The Brigham & Women's Hospital, Inc. |
Suppression of vascular disorders by mucosal administration of heat shock protein peptides
|
|
US7261896B2
(en)
|
2000-05-24 |
2007-08-28 |
United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health |
Methods for preventing strokes by inducing tolerance to e-selectin
|
|
WO2002040039A2
(en)
|
2000-11-20 |
2002-05-23 |
Dow Global Technologies Inc. |
In vivo use of water absorbent polymers
|
|
US6932861B2
(en)
|
2000-11-28 |
2005-08-23 |
Fmc Corporation |
Edible PGA coating composition
|
|
TR200300731T2
(tr)
|
2000-11-28 |
2004-08-23 |
Fmc Corporation |
Yenebilir PGA kaplama bileşimi
|
|
ATE446751T1
(de)
*
|
2001-06-05 |
2009-11-15 |
Univ Chicago |
Verwendung von methylnaltrexon zur behandlung von immunsuppression
|
|
GB0203296D0
(en)
*
|
2002-02-12 |
2002-03-27 |
Glaxo Group Ltd |
Novel composition
|
|
ATE425744T1
(de)
*
|
2002-04-29 |
2009-04-15 |
Supernus Pharmaceuticals Inc |
Pharmazeutische formulierungen mit verbesserter bioverfugbarkeit
|
|
NZ537885A
(en)
*
|
2002-07-29 |
2007-11-30 |
Glaxo Group Ltd |
Sustained release formulations comprising a lamotrigine core and an outer coating
|
|
US8637512B2
(en)
*
|
2002-07-29 |
2014-01-28 |
Glaxo Group Limited |
Formulations and method of treatment
|
|
ES2528669T3
(es)
|
2003-04-08 |
2015-02-11 |
Progenics Pharmaceuticals, Inc. |
Formulaciones farmacéuticas que contienen metilnaltrexona
|
|
US20040202755A1
(en)
*
|
2003-04-08 |
2004-10-14 |
Myers Gale D. |
Speckled confection pieces
|
|
JP2006522817A
(ja)
*
|
2003-04-08 |
2006-10-05 |
プロジェニックス ファーマシューティカルズ，インコーポレーテッド |
過敏性腸症候群を処置するための末梢オピオイドアンタゴニスト、特にメチルナルトレキソンの使用
|
|
BRPI0409125A
(pt)
*
|
2003-04-08 |
2006-03-28 |
Progenics Pharm Inc |
terapia de combinação para constipação compreendendo um laxativo e um antagonista de opióide periférico
|
|
US7541344B2
(en)
|
2003-06-03 |
2009-06-02 |
Eli Lilly And Company |
Modulation of survivin expression
|
|
WO2005046663A1
(en)
|
2003-11-04 |
2005-05-26 |
Shire Laboratories, Inc. |
Compositions of quaternary ammonium containing bioavailability enhancers
|
|
JP5610663B2
(ja)
|
2003-11-04 |
2014-10-22 |
スパーナス ファーマシューティカルズ インコーポレイテッド |
トロスピウムの１日１回剤形
|
|
WO2005074908A1
(en)
|
2004-02-06 |
2005-08-18 |
Borody, Thomas, Julius |
Use of aminosalicylates in diarrhoea-predominent irritable bowel syndrome
|
|
AU2005327506B2
(en)
|
2004-10-20 |
2010-07-08 |
Antisense Therapeutics Ltd |
Antisense modulation of integrin alpha4 expression
|
|
US8691772B2
(en)
|
2005-01-04 |
2014-04-08 |
Yeda Research And Development Co. Ltd. |
HSP60, HSP60 peptides and T cell vaccines for immunomodulation
|
|
JP2008528497A
(ja)
*
|
2005-01-20 |
2008-07-31 |
プロジェニックス ファーマシューティカルズ，インコーポレーテッド |
メチルナルトレキソンおよび関連化合物の術後性胃腸障害のための使用
|
|
US8518962B2
(en)
|
2005-03-07 |
2013-08-27 |
The University Of Chicago |
Use of opioid antagonists
|
|
US9662325B2
(en)
|
2005-03-07 |
2017-05-30 |
The University Of Chicago |
Use of opioid antagonists to attenuate endothelial cell proliferation and migration
|
|
CA2600350C
(en)
|
2005-03-07 |
2015-02-10 |
The University Of Chicago |
Use of opioid antagonists to attenuate endothelial cell proliferation and migration
|
|
US8524731B2
(en)
|
2005-03-07 |
2013-09-03 |
The University Of Chicago |
Use of opioid antagonists to attenuate endothelial cell proliferation and migration
|
|
WO2006109312A2
(en)
*
|
2005-04-15 |
2006-10-19 |
Vascular Biogenics Ltd. |
Compositions containing beta 2-glycoprotein i-derived peptides for the prevention and/or treatment of vascular disease
|
|
AR057325A1
(es)
*
|
2005-05-25 |
2007-11-28 |
Progenics Pharm Inc |
Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
|
|
AR057035A1
(es)
|
2005-05-25 |
2007-11-14 |
Progenics Pharm Inc |
SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
|
|
US20080194611A1
(en)
*
|
2005-06-03 |
2008-08-14 |
Alverdy John C |
Modulation of Cell Barrier Dysfunction
|
|
US20070098790A1
(en)
*
|
2005-10-31 |
2007-05-03 |
David Jiang |
Nutritional supplement for the enhancement of the health of the liver
|
|
TWI489984B
(zh)
|
2006-08-04 |
2015-07-01 |
Wyeth Corp |
用於非經腸道傳輸化合物之配方及其用途
|
|
US7731604B2
(en)
*
|
2006-10-31 |
2010-06-08 |
Taylor Made Golf Company, Inc. |
Golf club iron head
|
|
WO2008080807A1
(en)
*
|
2007-01-05 |
2008-07-10 |
Ciba Holding Inc. |
Co-milling organic pigments with fumed silica
|
|
WO2008121352A2
(en)
|
2007-03-29 |
2008-10-09 |
Progenics Pharmaceuticals, Inc. |
Crystal forms of (r) -n-methylnaltrexone bromide and uses thereof
|
|
US8338446B2
(en)
|
2007-03-29 |
2012-12-25 |
Wyeth Llc |
Peripheral opioid receptor antagonists and uses thereof
|
|
TWI553009B
(zh)
|
2007-03-29 |
2016-10-11 |
普吉尼製藥公司 |
末梢性類鴉片受體拮抗劑及其用途
|
|
US9029383B2
(en)
*
|
2007-05-11 |
2015-05-12 |
The Trustees Of The University Of Pennsylvania |
Methods of treatment of skin ulcers
|
|
KR101461659B1
(ko)
|
2007-05-11 |
2014-11-17 |
토마스 제퍼슨 유니버시티 |
신경변성 질환 및 장애의 치료 및 예방 방법
|
|
JP2011504171A
(ja)
*
|
2007-11-13 |
2011-02-03 |
ハーキュリーズ・インコーポレーテッド |
栄養補助食品および医薬品の剤形のための水分散性腸溶性コーティング配合物
|
|
HUE041715T2
(hu)
*
|
2007-12-21 |
2019-05-28 |
Dr Willmar Schwabe Gmbh & Co Kg |
Ginkgo biloba levél-kivonat alkalmazása
|
|
EP2240489A1
(en)
|
2008-02-06 |
2010-10-20 |
Progenics Pharmaceuticals, Inc. |
Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
|
|
WO2009117669A2
(en)
|
2008-03-21 |
2009-09-24 |
The University Of Chicago |
Treatment with opioid antagonists and mtor inhibitors
|
|
US20110250278A1
(en)
|
2008-07-01 |
2011-10-13 |
University Of Chicago |
Particles containing an opioid receptor antagonist and methods of use
|
|
US20100034959A1
(en)
*
|
2008-08-07 |
2010-02-11 |
Vector Corporation |
High solids, high molecular weight polymer coating
|
|
CA2676881C
(en)
|
2008-09-30 |
2017-04-25 |
Wyeth |
Peripheral opioid receptor antagonists and uses thereof
|
|
JP2013545792A
(ja)
|
2010-12-17 |
2013-12-26 |
グラクソ グループ リミテッド |
眼疾患の処置および防止方法
|
|
WO2013045352A1
(de)
|
2011-09-30 |
2013-04-04 |
Basf Se |
Verfahren zur herstellung von festen pigmenthaltigen filmüberzugsmitteln in form von granulaten auf basis von magensaftresistenten filmbildnern für pharmazeutische dosierungsformen
|
|
US9173884B2
(en)
|
2011-11-30 |
2015-11-03 |
Trustees Of Boston College |
Inhibitors of phosphodiesterase 11 (PDE11)
|
|
CN104203231A
(zh)
|
2011-12-01 |
2014-12-10 |
葛兰素集团有限公司 |
治疗和预防眼疾病的方法
|
|
US8277842B1
(en)
*
|
2012-01-20 |
2012-10-02 |
Dart Neuroscience (Cayman) Ltd. |
Enteric-coated HT-2157 compositions and methods of their use
|
|
CN105378083B
(zh)
|
2013-03-27 |
2018-09-21 |
伊萨纳治疗有限公司 |
修饰的TGF-β寡核苷酸
|
|
JP6686013B2
(ja)
|
2014-10-17 |
2020-04-22 |
サリックス ファーマスーティカルズ，インコーポレーテッド |
腫瘍の進行を減弱させるためのメチルナルトレキソンの使用
|
|
EP3211081A1
(en)
|
2016-02-26 |
2017-08-30 |
Secarna Pharmaceuticals GmbH & Co. KG |
Novel approach for treating inflammatory disorders
|
|
US10647987B2
(en)
|
2016-02-26 |
2020-05-12 |
Secama Pharmaceuticals GmbH & Co KG |
Approach for treating inflammatory disorders
|
|
US10883108B2
(en)
|
2016-03-31 |
2021-01-05 |
The Schepens Eye Research Institute, Inc. |
Endomucin inhibitor as an anti-angiogenic agent
|
|
WO2018065589A1
(en)
|
2016-10-07 |
2018-04-12 |
Secarna Pharmaceuticals Gmbh & Co. Kg |
Novel approach for treating cancer
|
|
US11229662B2
(en)
|
2016-11-15 |
2022-01-25 |
The Schepens Eye Research Institute, Inc. |
Compositions and methods for the treatment of aberrant angiogenesis
|
|
WO2019070917A1
(en)
|
2017-10-03 |
2019-04-11 |
The Schepens Eye Research Institute, Inc. |
COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE DEGENERATION OF RETINAL PIGMENT EPITHELIUM AND METHODS USING SAME
|
|
CA3082643A1
(en)
|
2017-11-14 |
2019-05-23 |
The Schepens Eye Research Institute, Inc. |
Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
|
|
JP2022531415A
(ja)
|
2019-05-03 |
2022-07-06 |
セカルナ・ファーマシューティカルズ・ゲーエムベーハー・ウント・コ・カーゲー |
腫瘍の処置に使用するためのｐｄ－ｌ１アンチセンスオリゴヌクレオチド
|